Actively Recruiting
Study of New HyperSight CBCT Imaging for Guiding Radiation Therapy in Adults with Cancer
Led by Varian, a Siemens Healthineers Company · Updated on 2026-03-13
50
Participants Needed
4
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are examining a new imaging technology called HyperSight cone beam computed tomography CBCT in patients undergoing radiation therapy for various cancers including head and neck, breast, thoracic, liver, genitourinary, and gastrointestinal cancers. This new imaging system is designed to provide better image quality than conventional CBCT used for patient alignment during radiation treatment. The study aims to determine if HyperSight CBCT can improve the overall radiation therapy process by enabling additional tasks like radiation plan calculation. Participants will receive their daily radiation treatment using a Varian TrueBeam machine equipped with the HyperSight CBCT imager, which rotates around the patient on a C-shaped arm. For at least one and up to three treatment sessions, participants will also receive radiation on a system with conventional CBCT imaging. The study collects images from these two CBCT methods to compare their quality, including aspects such as contrast resolution, uniformity, and artifact reduction. During the study, participants will undergo imaging assessments throughout their radiation treatment, which typically lasts up to 9 weeks. Researchers will evaluate image quality measures, imaging times, patient tolerance of breath hold imaging, and the feasibility of using HyperSight CBCT for treatment planning. All imaging and treatment data will be analyzed to assess whether the new technology can support improved radiation therapy delivery and patient care.
CONDITIONS
Brief Title
Feasibility Study of CBCT for IGRT in Cancer Patients
Research Team
S
Sean Davidson
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here